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Abstract
Objective: The aim of this study was to conduct a pilot study testing whether single-dose, immediate-release dexmethyl-
phenidate (dMPH) can facilitate tic suppression in children and adolescents with attention-deficit/hyperactivity disorder
(ADHD) and Tourette’s disorder (TD) or chronic tic disorders. The primary hypothesis is that dMPH will improve behav-
iorally reinforced tic suppression in a standard tic suppression paradigm (TSP).
Methods: Ten children with ADHD and TD were given dMPH on one visit and no medication on another, using a random
crossover design. On both days, following a baseline period, subjects were reinforced for suppressing tics using a standard
TSP.
Results: Thirteen subjects were enrolled; 10 subjects (mean age 12.7 2.6; 90% male) completed all study procedures.
Relative to the no-medication condition, tics were reduced when children were given a single dose of dMPH. Behavioral
reinforcement of tic suppression resulted in lower rates of tics compared to baseline, but dMPH did not enhance this
suppression.
Conclusion: Preliminary results indicate replication of prior studies of behavioral tic suppression in youths with TD and
without ADHD. In addition, our findings indicate tic reduction (and not tic exacerbation) with acute dMPH challenge in
children and adolescents with ADHD and TD.
Introduction
Bidirectional overlap of attention-deficit/hyperactivitydisorder (ADHD) and tic disorders, including Tourette’s dis-
order (TD), has been frequently described in youths (Spencer et al.
1999a; Spencer et al. 1999b). Co-morbid ADHD is observed in
about half of clinically referred children and adolescents with TD,
and tic disorders are reported in up to a third of clinically referred
children with ADHD (Spencer et al 1999a; Coffey et al. 2000).
Both disorders are conceptualized as disorders of central nervous
system (CNS) disinhibition; neurobiological substrates for the over-
lapping motor, attentional, organizational, and planning dysfunc-
tion include basal ganglia and premotor and prefrontal pathways
(Robertson 2000; Jankovic 2001; Swerdlow and Young 2001).
Treatment of children and adolescents with co-morbid ADHD
and TD is challenging, and includes both pharmacological and
behavioral interventions. Two problems are often encountered in
treatment. First, there remains a general belief that use of stimulants
to treat ADHD symptoms in children with co-morbid tic disorders
is contraindicated because of concerns about possible tic exacer-
bation. However, studies over the past decade have provided con-
verging evidence that stimulants are beneficial for ADHD
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symptoms in children with ADHD and tic disorders, and tics do not
increase significantly (Spencer et al. 1999a; Gadow et al. 2007). In
fact, in one controlled four-arm study comparing clonidine, meth-
ylphenidate (MPH), and the combination to placebo in children and
adolescents with ADHD and chronic tics, tics reduced significantly
in those treated with MPH alone (The Tourette’s Syndrome Study
Group SSG 2002).
Second, there is concern that ADHD symptoms may diminish
efficacy of behavioral treatment in children with chronic tic dis-
orders. There is growing evidence for the therapeutic benefit of
habit reversal therapy (HRT), more recently described as com-
prehensive behavioral intervention for tics (CBIT) in patients with
TD (e.g.,Wilhelm et al. 2003;Woods et al. 2003; Deckersbach et al.
2006; Piacentini et al. 2010). However, preliminary results suggest
that the therapeutic benefit of HRT may be moderated by the pa-
tient’s attentional competence. Converging lines of evidence sug-
gest moderating effects of attention and response inhibition on
reinforced tic suppression (Peterson et al. 1998; Deckersbach et al.
2006; Himle and Woods 2006; Woods et al. 2008). Such evidence
arises from two primary sources.
The first line of evidence comes from laboratory experiments
using experimental paradigms to study tic suppression. Using the
tic suppression paradigm (TSP) developed by Woods and Himle
(2004), Woods and colleagues (2008) examined the ability of
children to voluntarily suppress their tics for different time dura-
tions (5 minutes, 25 minutes, and 40 minutes) while being re-
inforced with a monetary reward for 10-second tic-free intervals.
This study also examined rebound effects on tic frequency and
neuropsychological predictors of tic suppression. Thirteen chil-
dren, ranging in age from 10 to 17 years, completed the study at two
separate sites. Results indicated a nearly 80% reduction in tics with
behavioral reinforcement during the active tic suppression phase,
regardless of the duration (i.e., 5, 25, or 40 minutes). Results also
revealed no rebound (beyond return to baseline) in tic frequency
following periods of suppression.
Results also indicated specific predictors of impaired ability to
suppress tics with a behavioral reward. Specifically, the number of
errors of omission on the Conners’ Continuous Performance Test
(CPT) (a measure of deficient attentional functioning) was signif-
icantly negatively correlated with magnitude of tic suppression
both in the 25- and 40-minute suppression conditions. Such results
are consistent with earlier findings by Himle and Woods (2005),
who demonstrated that tic suppression ability was significantly
negatively correlated with scores on the Attention Problems sub-
scale of the Child Behavior Check List (CBCL) (Achenbach 2001),
and a study by Peterson and colleagues (1998) suggesting that tic
suppression recruits a number of brain regions involved in atten-
tional competence.
The second line of evidence comes from a clinical trial (Deck-
ersbach et al. 2006) in which 30 adults with TD were randomly
assigned to either HRT or a supportive psychotherapy control
condition. Results replicated earlier findings demonstrating the
efficacy of behavior therapy over the control condition (e.g., Azrin
and Peterson 1990; Wilhelm et al. 2003). The investigators also
showed that poor response on a ‘‘go-no go’’ task (a task measuring
attentional competence) was a significant predictor of poor re-
sponse to HRT. Taken together, laboratory-based studies and the
clinical trial suggest that successful tic suppression using behav-
ioral procedures may be significantly impaired by compromised
attentional functioning.
On the basis of these findings, a logical next step would be to
determine if pharmacological agents designed to enhance atten-
tional/inhibitory processeswould improve the efficacyof behavioral
procedures designed to facilitate tic suppression. Psychostimulant
medication, well established in the treatment of ADHD, may be a
useful agent in this regard (DeVito et al. 2009). Reinforced tic
suppression can be assessed via a TSP developed by Woods and
Himle (Woods and Himle 2004; Himle and Woods 2005).
We describe a pilot challenge study using a short-acting psy-
chostimulant known to enhance attention—dexmethylphenidate
(dMPH)—to evaluate its effect on reinforced tic suppression in
children with ADHD and co-morbid TD or chronic tic disorder. On
the basis of previous work in both ADHD and TD, we seek to test
three primary hypotheses. First, we predict that dMPHwill produce
a decrease in tic rate relative to a no-medication control condition.
Second, consistent with prior work on the effects of reinforcement
on establishing tic suppression (Woods and Himle 2004; Himle and
Woods 2006; Woods et al. 2008), we predict that tic rates will be
lower when children are reinforced for successful suppression
when compared to a no-suppression baseline condition, and that
successful suppression will not result in a tic rate rebound ex-
ceeding baseline levels. Finally, given that psychostimulants have
been useful in ameliorating deficits in attention and response in-
hibition, and these processes have been linked to successful tic
suppression, we predict that behaviorally reinforced tic suppression
will be more successful in the dMPH condition as compared to the
no-drug condition.
Methods
Subjects
Subjects were recruited between November, 2008, and October,
2009, through the Tics and Tourette’s Clinical and Research Pro-
gram, referrals from local professionals, the Tourette Syndrome
Association, and by telephone screening of interested parties soli-
cited by advertising. All subjects were evaluated with a compre-
hensive psychiatric assessment by the first or senior author, both
with expertise in the diagnosis and treatment of tic disorders.
Written informed consent of parents and assent of child were ob-
tained. All study procedures were approved by the institutional
review boards (IRB) at University of Wisconsin–Milwaukee and
New York University Langone Medical Center.
Approximately 51 subjects were screened for this study and 13
were enrolled. Subjects were eligible for inclusion if they met the
following criteria: (1) Age 10–17 years (inclusive) when informed
consent was obtained; (2) Diagnostic and Statistical Manual of
Mental Disorders, 4th edition, Text Revision (DSM-IV-TR)
(American Psychiatric Association 2000) diagnostic criteria for TD
or chronic motor/vocal tic disorder (CTD) confirmed by the
Computerized Diagnostic Interview Schedule for Children–4th
edition (CDISC4) (Shaffer et al. 2003); (3) DSM-IV-TR diagnostic
criteria for co-morbid ADHD, any subtype, confirmed by the
CDISC4; (4) Yale Global Tic Severity Scale (YGTSS) (Leckman
et al. 1989) Total Tic Score 14 for TD or 10 for CTD; (5)
exhibited one or more motor and/or vocal tics at a rate of at least
1 tic per minute averaged across a 10-minute videotaped observa-
tion; (6) intellectual functioning was at least in the low-average
range or above as indicated by a score of greater than 75 on the
Wechsler Abbreviated Scale of Intelligence (WASI) (Wechsler
1999); (7) no history of behavioral treatment for tics (greater than
3 weeks in duration) or other treatment in which suppression
strategies were a primary component of the intervention; (8) current
tic medication (a-adrenergic agonists, typical or atypical neuro-
leptics) at the time of the study was allowed but had to remain stable
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at the same dose throughout the study period; (9) previous treat-
ment with stimulants was allowed if the subject had not received
stimulants for at least 48 hours prior to testing procedures; and (10)
ADHD symptoms must have been associated with impairment in at
least one domain (home, school).
Subjects were excluded from the study if they met any of the
following exclusion criteria: (1) subjects with pervasive develop-
mental disorder, schizophrenia, major depressive disorder, bipolar
disorder, or substance abuse disorder; (2) subjects currently re-
ceiving stimulant medication who could not temporarily dis-
continue it for study procedures; (3) subjects with any medical
condition that would contraindicate use of a stimulant, such as
seizure disorder, previous hypersensitivity to MPH, glaucoma, or a
significant cardiac history, including fainting or dizziness, seizures,
rheumatic fever, chest pain or shortness of breath with exercise,
unexplained change in exercise tolerance, palpitations, increased
heart rate, hypertension, heart murmur other than benign functional
murmur, or current viral illness with chest pains or palpitations; (4)
subjects with a family history of sudden or unexplained death in
someone less than 35 years of age, sudden death during exercise,
cardiac arrhythmias, cardiomyopathy including hypertrophic car-
diomyopathy (HCM), dilated cardiomyopathy or right ventricu-
lar cardiomyopathy, long QT syndrome, short QT syndrome or
Brugada syndrome, Wolf–Parkinson–White or abnormal cardiac
rhythyms, event requiring resuscitation in family members less
than age 35, including syncope requiring resuscitation, or Marfan
syndrome; (5) subjects with abnormal electrocardiogram (ECG)
at baseline, including prolongation of the QTc interval greater
than 450msec for males and 470msec for females; (6) subjects
who meet full criteria for obsessive-compulsive disorder or an-
other anxiety disorder requiring pharmacological or behavioral
treatment.
Two enrolled subjects dropped out prior to completion of the
study procedures, one for lack of interest in the study after consent
was obtained and the other for failure to meet intellectual func-
tioning criteria. One subject was excluded after completing study
procedures for not meeting the inclusion criterion of exhibiting one
or more motor and/or vocal tics at a rate of at least 1 tic per minute
averaged across a 10-minute videotaped observation. One subject
was 8 years old, but was allowed to enroll because he met all other
inclusion and exclusion criteria and was able to understand and
comply with study procedures.
The final study sample included 10 children and adolescents,
ages 8–16 years, with a DSM-IV-TR diagnosis of TD and co-
morbid ADHD, any subtype.
Design
Overview of Study Procedures. The study occurred over
3 days. Following initial baseline evaluation on day 1, one exper-
imental session occurred each day on days 2 and 3. On day 1, each
subject received an initial evaluation, which included an assess-
ment battery designed to provide sociodemographic information,
ensure that inclusion/exclusion criteria were met, and confirm a
diagnosis of TD or CTD andADHD. Demographic information and
treatment history (pharmacological and behavioral) were collected
for each subject using a demographics form and clinical interview.
Current medication status and medical and psychiatric history were
also obtained. Subjects were overtly videotaped for 10 minutes for
observation to determine whether or not the subject met inclusion
criteria of at least 1 tic per minute and to ascertain a list of subject-
specific tics. The YGTSS was administered as a semistructured
interview to parent and subject by one of the investigators (G.L. or
B.C.) at baseline. All subjects received an ECG. Subjects with
abnormal ECG readings were referred for a full cardiology evalu-
ation; written clearance was obtained from a pediatric cardiologist
prior to participating in study experimental procedures.
On days 2 and 3, the subject received no medication for 1 day
and a single, immediate release dose of dMPH (0.15mg/kg) on the
other. The dose administered was designed to fall in the typical
therapeutic range for treatment of ADHD. The order of medication
versus no medication was randomly assigned. One hour post dMPH
dose, or immediately after arrival on the day no medication was
given, attention was evaluated with a CPT, followed 15 minutes
later by tic suppression evaluation with TSP (as described below).
Days 2 and 3 were held at approximately the same time of day to
avoid any circadian rhythm effects in attention or tics.
All experimental sessions took place in a 10-foot15-foot ob-
servation room equipped with a one-way mirror and video re-
cording equipment to allow for covert observation and recording.
All conditions in the observation room were identical for each
experimental session; placement of the equipment, including the
token dispenser and camera were the same for each experimental
session. All sessions were video recorded, with videotapes sent to
the University of Wisconsin–Milwaukee for data coding. Video
raters were blind to participants’ medication status. Subjects were
unaware of being observed or videotaped during the TSP and were
debriefed at the end of the study.
Vital signs (pulse, blood pressure) were obtained on day 1 and
before and after TSP procedures on days 2 and 3. The Safety
Monitoring Uniform Report Form (SMURF) (Greenhill et al. 2004)
was administered by one of the investigators on day 1, and after
TSP procedures on days 2 and 3.
Tic suppression paradigm
The TSP involved exposing the subjects to three different tic
suppression conditions: (1) a 10-minute baseline condition (BL)
during which subjects were told not to suppress their tics; (2) a
10-minute suppression condition (SUP) during which subjects were
reinforced for suppressing their tics using a standard tic suppression
protocol; and (3) a 5-minute rest condition (REST) during which
subjects were instructed not to suppress their tics. After the initial
three conditions were presented, the suppression and rest condi-
tions were repeated once. On each day, each subject received the
following sequence of components for a total of 40 minutes: BL,
SUP, REST, SUP, REST.
Baseline. During the 10-minute BL condition, the subject was
seated in the observation room by him/herself with a token dis-
penser (a 12-inch12-inch24-inch box with an attached, non-
functioning web camera and a clear plastic receptacle attached to
the front) placed in front of him/her. Following the protocol es-
tablished by Woods and Himle (2004), the subject was told by a
research assistant that the machine is a ‘‘tic detector’’ which would
monitor and count the subject’s tics. The device was actually a
token dispenser, which was manually operated by study personnel
from behind the one-way mirror. The subject was asked to sit in
front of the machine for 10 minutes and was told to tic freely as
much or as little as needed while remaining in his/her seat with his/
her arms on the arm rest of the chair or in his/her lap. The subject
was then asked to repeat the instructions to ensure that he/she un-
derstood the task. No instructions to suppress were delivered and no
tokens were delivered during the BL condition.
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Reinforced suppression. During the 10-minute SUP condi-
tions, the subject remained seated with the token dispenser directly
in front of him/her. The subject was told again that the device is a
‘‘tic detector,’’ which would monitor and count his/her tics. To
produce reinforced tic suppression, the subject was told that he/she
could earn a token for each 10-second interval during which he/
she had no tics. The subject was also told that each token would
be exchangeable for a small monetary reward upon completion of
the study. Next, the research assistant provided a detailed overview
of the subject-specific tics the subject was to suppress. Subject-
specific tics were ascertained from tics reported on the YGTSS and
from tics observed and identified during the 10-minute video ob-
servation at visit 1. The subject was then asked to repeat the in-
structions to ensure that he/she understood the task.
During the suppression component, the ‘‘tic detector’’ was
controlled by a study investigator and research assistant observing
from behind the one-way mirror. For each consecutive 10-second
interval during which the subject did not have a tic, a token was
delivered into a receptacle visible to the subject on the front of the
token dispenser. Whenever a tic was observed, the 10-second in-
terval was reset without token delivery. Each subject received the
same compensation at the end of the study, regardless of the
number of tokens earned.
Rest. During the 5-minute REST component, the subject re-
mained seated with the token dispenser directly in front of him/her.
The subject was reminded by the research assistant that the device
was a ‘‘tic detector,’’ which monitored and counted his/her tics. The
subject was specifically instructed not to attempt tic suppression
during the REST condition. He or she was told to tic if necessary.
The subject was then asked to repeat the instructions to ensure that
he/she understood the task.
Measurements and analytic methods
Reinforced tic suppression was measured using videotaped tic
counts during the TSP. ADHD symptoms were measured using the
ADHD Rating Scale (ADHD-RS; Conners 1997). Attention was
measured by the CPT II (Conners 2000). Tic severity was measured
using the YGTSS (Leckman et al. 1989). Adverse events were
collected using the SMURF after each experimental trial (Greenhill
et al. 2004). Adverse events were defined as any undesirable change
from the subject’s baseline condition, including any intercurrent
illness that occurs during the study, whether considered related to
the investigational procedures or not.
Descriptive measures, including sociodemographic and diag-
nostic data, were tabulated with means, standard deviations, and
proportions where appropriate. A 2 (drug vs. no drug)3 (baseline
vs. suppression vs. rest) within-subjects analysis of variance
(ANOVA) was conducted to compare tics per minute observed
under each condition.
Results
Sociodemographic data
Sociodemographic data are described in Table 1. The sample
included 9 males (90%) and 1 female (10%) with a mean age of
12.7 (standard deviation [SD]¼ 2.6). All 10 subjects (100%) met
DSM-IV-TR criteria for TD and co-morbid ADHD. Five subjects
(50%) met criteria for ADHD Combined type and 5 subjects (50%)
met criteria for ADHD Inattentive type. Seven subjects (70%)
self-identified as white non-Hispanic and 3 subjects (30%) self-
identified as Hispanic. Subjects had a mean intelligence quotient
(IQ) of 104 (SD¼ 13.3). Seven subjects (70%) had normal ECG
readings; 3 (30%) subjects were referred for cardiology consulta-
tion for abnormal readings, and were cleared by a cardiologist prior
to participation in the experimental procedures.
Mean baseline YGTSS motor tic score was 13.2 (SD¼ 3.5)
(mild-to-moderate severity), vocal tic score was 10.6 (SD¼ 5.0)
(mild severity), and total tic score was 23.8 (SD¼ 7.5) (mild-to-
moderate severity). Mean baseline YGTSS impairment scores were
18.0 (SD¼ 8.9) (minimal-to-mild severity) and YGTSS global
severity scores of 41.8 (SD¼ 13.4) (mild-to-moderate severity)
(see Table 2). Mean ADHD-RS score at baseline was 25.3
(SD¼ 10.8) (mild to moderate).
Table 1. Sociodemographic Data (n¼ 10)
Mean SD Range
Age 12.7 2.6 8–16
IQ 104 13.3 85–118
dMPH dose (mg) 7.5 3.1 2.5–12.5
N %
Male 9 90%
Hispanic 3 30%
White non-Hispanic 7 70%
Tourette’s disorder diagnosis 10 100%
ADHD diagnosis 10 100%
Combined type 5 50%
Inattentive type 5 50%
ADHD-RS 25.3 10.8 9–43
Concomitant medications 7 70%
Abbreviations: SD¼ standard deviation; IQ¼ intelligence quotient;
dMPH¼ dexmethylphenidate; ADHD¼ attention-deficit/hyperactivity dis-
order; ADHD-RS¼ADHD Rating Scale.
Table 2. Yale Global Tic Severity Scale Subscale Scores by Study Condition
Baseline Nonmedication Medication
Mean SD Range Mean SD Range Mean SD Range
Motor tic 13.2 3.5 8–18 13.6 2.9 9–19 12.1 2.0 10–15
Vocal tic 10.6 5.0 0–17 8.6 4.8 0–15 4.9 6.9 0–16
Total tic 23.8 7.5 10–35 22.1 7.6 9–34 17.0 8.4 10–31
Impairment score 18.0 8.9 10–40 22.8 7.6 20–40 19.4 9.4 10–40
Global severity 41.8 13.4 20–64 45 10.6 29–62 36.4 15.2 20–63
Abbreviations: SD¼ standard deviation.
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Mean weight of the sample was 128.8 pounds (SD¼ 48.0) and
mean height was 61.8 inches (SD¼ 5.9) at baseline. Subjects re-
ceived mean dose of 7.5mg (SD¼ 3.1) of dMPH during the medi-
cation condition. Mean systolic (SBP) and diastolic blood pressure
(DBP) at baseline were 114.7 (SD¼ 9.1) and 62.8 (SD¼ 3.6), re-
spectively. Mean sitting pulse reading at baseline was 74.0 (SD¼
19.4). Blood pressure and sitting pulse readings were recorded be-
fore and after TSP during each study condition. No significant dif-
ferences between SBP and DBP or pulse rates were found between
readings before or after TSP, regardless of medication status.
Seven (70%) subjects were taking concomitant medications
during this study. These medications included clonidine, ar-
ipiprazole, guanfacine, lamotrigine, and benztropine for TD, cita-
lopram for obsessive-compulsive disorder (OCD), budesonide and
albuterol for asthma, and fluoxetine and sertraline for anxiety.
Effects on tics
A 2 (drug vs. no drug)3 (baseline, suppression, rest) within-
subjects ANOVA was conducted to test the three primary hy-
potheses. Confirming our first hypothesis, results showed a main
effect of drug, F(1,9)¼ 5.41, p< 0.05, Z2¼ 0.38; tics occurred less
frequently when subjects were taking dMPH (M¼ 1.98 tics per
minute, standard error [SE]¼ 0.40) than when they were medica-
tion free (M¼ 3.14, SE¼ 0.59). Our second hypothesis was also
confirmed; the main effect of suppression condition was statisti-
cally significant, F(2,18)¼ 7.74, p< 0.01, Z2¼ 0.46. As predicted,
when reinforced for tic suppression (M¼ 1.04 tics per minute,
standard error [SE]¼ 0.22), children exhibited significantly fewer
tics compared to baseline (M¼ 2.86, SE¼ 0.58; p< 0.01) or rest
(M¼ 3.77, SE¼ 0.83, p< 0.01) conditions. Consistent with pre-
vious reports (Himle and Woods 2006; Woods et al. 2008), there
was no evidence of rebound in tics (beyond return to unmedicated
baseline) following suppression regardless of being in the drug or
no drug condition ( p¼ 0.30). Contrary to expectations, our results
did not support our third hypothesis; dMPH did not significantly
improve tic suppressibility (see Fig. 1), as the interaction between
drug and suppression condition was not significant, F(2,18)¼ 0.93,
p¼ 0.41, Z2¼ 0.09.
Effects on CPT measures
To ensure that dMPH significantly improved attentional func-
tioning as measured by the CPT, separate one-way (baseline, drug
day, no drug day) within-subjects ANOVAs were conducted for
errors of commission and errors of omission. Data from 3 subjects
were unusable as a result of computer malfunction. As predicted,
errors of commission significantly differed between the three
conditions, F(2,12)¼ 5.49, p< 0.05, Z2¼ 0.48; fewer errors of
commission occurred during the dMPH condition (M¼ 42.97,
SE¼ 6.2) than during the baseline condition (M¼ 53.08,
SE¼ 2.89; p< 0.05) or during the no-drug day (M¼ 49.54,
SE¼ 5.03; p< 0.05). Contrary to our prediction, errors of omission
were not differentially effected across conditions, F(2,12)¼ 0.43,
p¼ 0.66, Z2¼ 0.07. There were no statistically significant differ-
ences between the baseline (M¼ 49.17, SE¼ 4.4), dMPH
(M¼ 46.51, SE¼ 2.1), and the no-drug conditions (M¼ 49.57,
SE¼ 3.4).
Adverse events
Subjects tolerated the procedures generally well, and any ad-
verse events were minor. Seven (70%) subjects experienced at least
one minor adverse event during the study. The most common ad-
verse events possibly related to study drug were drowsiness or
sedation (20%) and stomach discomfort (20%).
Discussion
The clinical management of children with TD and co-morbid
ADHD is challenging, and our study provides encouraging infor-
mation for clinicians. Supporting our first hypothesis, our results
demonstrate that a one-time dose of short-acting stimulants does
not increase tics in children with ADHD and TD, and may, in fact,
be beneficial. Second, our results replicate prior research demon-
strating that reinforced tic suppression yields significant tic re-
duction and does not lead to rebound effects. Contrary to our third
hypothesis, our results showed that one-time administration of
dMPH did not significantly improve tic suppression ability. This
was true even though a study indicator of response inhibition (the
CPT–Errors of Commission) was improved in the dMPH condition
when compared to the no-treatment condition.
Reasons for the failure to support our hypothesis that dMPH
would enhance reinforced tic suppression are unclear, but a number
of possible explanations exist. First, it is possible that in our sample
stimulant-associated tic reduction yielded a floor effect, in that
further benefit simply could not be achieved because tics were
reduced so significantly by the behavioral suppression task alone.
Second, the data suggest that tic suppression abilities were being
slightly enhanced by dMPH, and perhaps relatively low power to
detect the interaction prevented the detection of the small effect. A
third possibility is that it is not the inhibitory deficits in ADHD that
are related to poor suppression, but rather deficits in working
memory (e.g., ability to retain instructions), attentional selection
(e.g., focus on something else in the suppression environment), or
interference control (e.g. distraction by other stimuli) that lead to
suppression deficits. Last, a possible explanation for our lack of
disrupted suppression in the nondrug condition is that perhaps the
ADHD symptoms were not severe enough to disrupt suppression.
FIG. 1. Mean number of tics per minute under the non-
medication and one-time dose of dexmethylphenidate (dMPH)
conditions during the TSP.
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Supporting the role of attentional selection in behavioral tic sup-
pression is our finding that errors of omission did not reduce sig-
nificantly with the stimulant in these children. Future research will
need to be conducted to examine these possibilities.
Limitations
Some limitations of the study design need to be taken into ac-
count. First, our sample size was small and subjects were recruited
from a specialized clinic. Thus, findings may not generalize to
nonspecialty settings. Second, 70% of subjects were receiving
medication for TD, anxiety, OCD, or asthma, and our results might
have differed if the subjects were not receiving concomitant med-
ication. Third, investigators, parents, and subjects were not blind to
medication status, because medication was administered openly.
Nevertheless, order of receiving medication was randomized, and
video raters were blind to study condition. In addition, because we
only used single doses of mid-range immediate release dMPH, we
were unable to explore a dose range of effects on ADHD and tics.
However, our results appear to be valid, in that CPT commission
errors reduced on medication compared to no medication, repli-
cating known effects of psychostimulants on CPT (Losier et al.
1996). Clearly, future research is needed to replicate our results
with placebo control conditions and a substantially larger sample
before drawing firm conclusions.
Conclusion and clinical implications
Preliminary results suggest that dMPH does not appear to en-
hance tic suppressibility in children with ADHD and TD; however,
given the small sample size, and the possibility of a floor effect,
firm conclusions cannot be drawn yet. Nevertheless, important
findings emerged. First, there was a clear tic-reduction effect, and
not exacerbation, with a one-time dose of dMPH compared to no
medication in these children. Second, youths with TD and ADHD
appear to be able to suppress their tics with a behavioral reward
comparable to youths with TD without ADHD. Taken together,
these findings justify the need for further studies with larger
numbers of subjects and suggest that treatment with dMPH
(0.15mg/kg/dose) should be further explored in treatment of youths
with co-morbid ADHD and TD.
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